
OLD Category: immuno-oncology
March 1, 2020 / J Mol Cell Biol
Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors
February 26, 2020 / Clin Cancer Res
Induced tumor heterogeneity reveals factors informing radiation and immunotherapy combinations
February 25, 2020 / Expert Opin Biol Ther.
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view
February 25, 2020 / Neuroendocrinology.
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours
February 20, 2020 / Haematologica.
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
February 18, 2020 / Nat Commun.
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
February 1, 2020 / J Immunother Cancer.
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
January 31, 2020 / Clin Cancer Res
Predictive biomarkers for adjuvant capecitabine benefit in early stage triple negative breast cancer in the FinXX clinical trial
January 31, 2020 / Nat Commun